Whitney Ijem is a Director and Senior Biotechnology Analyst on the Healthcare Research team at Guggenheim Securities, where she focuses on gene therapy and rare disease. Ms. Ijem joined Guggenheim from Tourbillon Capital, where she was a healthcare analyst focused on companies across the therapeutics space. Prior to Tourbillon, she was a biotech analyst in the J.P. Morgan Equity Research Healthcare group. Before joining J.P. Morgan, Ms. Ijem was a biotech analyst at Canaccord Genuity. She began her career at Arcoda Capital. Ms. Ijem received her M.S. in Biomaterials Science from New York University and her B.S. in Biomedical Engineering from Washington University in St. Louis.